{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06055881",
            "orgStudyIdInfo": {
                "id": "GMROR2232"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2023-03208",
                    "type": "REGISTRY",
                    "domain": "CTRP (Clinical Trial Reporting Program)"
                },
                {
                    "id": "22-002943",
                    "type": "OTHER",
                    "domain": "Mayo Clinic Institutional Review Board"
                },
                {
                    "id": "GMROR2232",
                    "type": "OTHER",
                    "domain": "Mayo Clinic Radiation Oncology"
                }
            ],
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)",
            "officialTitle": "Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "primary-breast-oligoprogressive-sites-treated-with-radiotherapy-to-obviate-the-need-to-change-systemic-therapy-boss"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-23",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-10-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-20",
            "studyFirstSubmitQcDate": "2023-09-26",
            "studyFirstPostDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-24",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Kimberly S. Corbin",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease.",
            "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To assess whether radiotherapy can provide clinically significant freedom from a change in systemic therapy (defined as for at least 6 months) for well-selected patients with oligoprogressive metastatic breast cancer.\n\nOUTLINE: This is an observational study.\n\nPatients undergo blood sample collection and complete questionnaires on study."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 45,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Observational",
                    "description": "Patients undergo blood sample collection and complete questionnaires on study.",
                    "interventionNames": [
                        "Other: Non-Interventional Study"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Non-Interventional Study",
                    "description": "Non-interventional study",
                    "armGroupLabels": [
                        "Observational"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Freedom from a change in systemic therapy",
                    "description": "Freedom from a change in systemic therapy defined as no change in systemic therapy at 6 months after radiotherapy and patient survival at 6 months after radiotherapy. Treatment failure would indicate that there is no longer stability of systemic therapy (and thereby requires a change in systemic therapy to a different agent).",
                    "timeFrame": "At 6 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* \\* Age \u2265 18 years.\n\n  * Histological confirmation of primary breast cancer.\n  * Patients with metastatic breast cancer and at least 12 months of clinical response to first-line systemic therapy, with the subsequent development of 1-3 extracranial sites of oligoprogressive disease.\n\n    * NOTE: patients with de novo metastatic disease and those developed metastatic disease after initially localized disease can both be included.\n  * Patients with metastatic breast cancer and at least 6 months of clinical response to second-line systemic therapy (or further, e.g., third- or fourth-line), with the subsequent development of 1-3 extracranial sites of oligoprogressive disease.\n  * ECOG Performance Status (PS) \u2264 2.\n  * Negative urine or serum pregnancy test done \u2264 7 days prior to registration, for women of childbearing potential only.\n  * Ability to complete questionnaire(s) by themselves or with assistance.\n  * Provide written informed consent.\n  * Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).\n  * Willing to provide blood samples for correlative research purposes.\n\nExclusion Criteria:\n\n* \\* Male patients.\n\n  * Nursing or pregnant women.\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception.\n  * Patients with triple negative disease (negative for ER, PR, and HER2).\n\n    \u2022 Active second primary malignancy\n  * \\> 3 extracranial sites of oligoprogressive disease\n  * Active CNS disease. Patients with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed.\n  * Active connective tissue disease that is felt by the treatment team to pose an excess risk of toxicity.\n  * Prior radiation that overlaps with the intended treatment volume such that, in the opinion of the patient's Radiation Oncologist, radiotherapy to progressing sites will not be safe.\n\n    * NOTE: patients with some dose overlap with prior radiotherapy that is deemed safe by the patient's Radiation Oncologist can be included in the trial.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with metastatic breast cancer and at least 12 months of clinical response to first-line systemic therapy, with the subsequent development of 1-3 extracranial sites of oligoprogressive disease",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Kimberly S. Corbin, M.D.",
                    "affiliation": "Mayo Clinic in Rochester",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Arizona",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85259",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Sarah E. James, M.D., Ph.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "Mayo Clinic in Florida",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32224",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Laura A. Vallow, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "Mayo Clinic in Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Clinical Trials Referral Office",
                            "role": "CONTACT",
                            "phone": "855-776-0015",
                            "email": "mayocliniccancerstudies@mayo.edu"
                        },
                        {
                            "name": "Kimberly S. Corbin, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}